TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.
Ahronian LG, Sahu S, Zhang M, Patel AS, Geng K, Bhattacharya R, Falchook GS, Goldman JW, Spira AI, Punekar SR, Spigel DR, Wang JS, Skoulidis F, Stephens J, Meynardie M, Powell JM, Lopez A, Ranieri M, Ploszaj MA, Tan YJ, Lee YT, Yu Y, Deng J, Chen T, McCarren P, Tsai A, Hussain SS, Doyon B, Amemiya K, Ermolieff J, Shahagadkar P, Das NM, Flynn LR, Shields JA, Danielczyk L, McMillan BJ, Mignault A, Meier SR, Wu HJ, Guerin DJ, Whittington DA, Min C, Sienczylo I, Maxwell JP, DiBenedetto HJ, Watanabe H, Haines BB, Huang A, Crystal A, Andersen JN, Wu X, Wong KK.
Ahronian LG, et al. Among authors: chen t.
Cancer Res. 2025 Oct 15;85(20):3966-3982. doi: 10.1158/0008-5472.CAN-25-0998.
Cancer Res. 2025.
PMID: 40882030
Free PMC article.